Clinical Trials Logo

Clinical Trial Summary

This protocol describes the pivotal accuracy study for the IdentiClone Dx IGH (IC IGH Dx) Assay. The intent of the accuracy study is to demonstrate agreement between the results of the IC IGH Dx Assay and a predicate devise or assay on retrospective and residual de-identified DNA extracted from peripheral blood (PB) samples from individuals with suspected B-Cell Lymphoproliferations. The predicate device will be the LymphoTrack Dx IGH (FR1/FR2/FR3) Assays - MiSeq (LT Dx IGH-CE-IVD), which is a CE-IVD assay with a similar intended use as the IC IGH Assay on the same sample type.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06112301
Study type Observational
Source Invivoscribe, Inc.
Contact
Status Recruiting
Phase
Start date January 2, 2024
Completion date August 1, 2024